Downregulation of midkine induces cisplatin resistance in human oral squamous cell carcinoma

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1674-1680

  Tomoko, Ota ^a   Jono, Hirofumi ^a   Kazutoshi, Ota ^a   Shinriki, Satoru ^a   Ueda, Mitsuharu ^a   Sueyoshi, Takanao ^a   Nakatani, Ken ^b   Hiraishi, Yukihiro ^b   Wada, Takeshi ^b   Fujita, Shigeyuki ^b   Obayashi, Konen ^a   Shinohara, Masanori ^a   Ando, Yukio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; Drug resistance; Midkine; Oral squamous cell carcinoma

Indexed keywords

ABC TRANSPORTER; CISPLATIN; CYCLIN D1; CYCLIN E; CYCLIN E1; FIBROBLAST GROWTH FACTOR; MEDKINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER GROWTH; CANCER RESISTANCE; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INDUCTION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYTOKINES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS;

EID: 84858176590     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1684     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Petersen PE: The World Oral Health Report 2003: continuous improvement of oral health in the 21st century - the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol 31 (Suppl 1): 3-23, 2003.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
4. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098, 2003. (Pubitemid 37464533)
5. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
6. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955, 2000. (Pubitemid 30148259)
7. Jamieson ER and Lippard SJ: Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99: 2467-2498, 1999.
8. Brozovic A and Osmak M: Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251: 1-16, 2007. (Pubitemid 46589761)
9. Zhang P, Zhang Z, Zhou X, Qiu W, Chen F and Chen W: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 6: 224, 2006.
10. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005. (Pubitemid 41130944)
11. Kadomatsu K and Muramatsu T: Midkine and pleiotrophin in neural development and cancer. Cancer Lett 204: 127-143, 2004. (Pubitemid 38167717)
12. Ota K, Fujimori H, Ueda M, et al: Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer 99: 655-662, 2008.
13. Nakagawara A, Milbrandt J, Muramatsu T, et al: Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 55: 1792-1797, 1995.
14. Mishima K, Asai A, Kadomatsu K, et al: Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 233: 29-32, 1997. (Pubitemid 27402545)
15. Nakatani K, Nakamura M, Uzawa K, et al: Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. Oncol Rep 13: 709-714, 2005.
16. O'Toole SA, Sheppard BL, McGuinness EP, Gleeson NC, Yoneda M and Bonnar J: The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. Cancer Detect Prev 27: 47-54, 2003. (Pubitemid 36345485)
17. Sandra F, Harada H, Nakamura N and Ohishi M: Midkine induced growth of ameloblastoma through MAPK and Akt pathways. Oral Oncol 40: 274-280, 2004. (Pubitemid 38121564)
18. Jin Z, Lahat G, Korchin B, et al: Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res 14: 5033-5042, 2008.
19. +-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B. Cancer Chemother Pharmacol 63: 643-650, 2009.
20. Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535, 2008. (Pubitemid 351738162)
21. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
22. Xu Y, Qu X, Zhang X, et al: Midkine positively regulates the proliferation of human gastric cancer cells. Cancer Lett 279: 137-144, 2009.
23. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997.
24. Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181, 2001. (Pubitemid 32751613)
25. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31, 2007.
26. Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T and Kadomatsu K: Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by Midkine. J Biochem 127: 269-277, 2000. (Pubitemid 30136910)
27. Mirkin BL, Clark S, Zheng X, et al: Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 24: 4965-4974, 2005. (Pubitemid 41129100)